The Depo-Provera lawsuit 2026 litigation has reached its most consequential milestone yet: a global settlement in principle reached between Pfizer and plaintiffs’ lead counsel in June 2026 — before a single bellwether trial, before a Daubert ruling, and before a decision on preemption. As of October 2026, more than 6,412 lawsuits are pending in federal court, with 6,524 total cases filed. Pfizer and plaintiffs’ leadership signed a Master Settlement Agreement on July 21, 2026, though financial terms remain confidential and not every claim is covered. Pfizer estimates the proposed settlement could resolve approximately 80% of the pending MDL cases, while the remaining lawsuits will continue through the court process, including a Rule 702 hearing on expert testimony admissibility scheduled for September 18, 2026. For anyone tracking MDL 3140, the next several months — covering settlement registration opening in November 2026, causation hearings for non-settling claims, and the fate of state-court filings — are the most consequential in the history of this litigation.
The Depo-Provera MDL: Where Things Stand in 2026
MDL 3140 was consolidated in the Northern District of Florida under Judge M. Casey Rodgers and has grown into one of the fastest-moving — and now most dramatically resolved — mass tort proceedings in the country. As of October 2026, 6,412 lawsuits are pending in federal court, with 6,524 total cases filed in the multidistrict litigation (MDL), which is similar to a Depo-Provera class action lawsuit. That figure represents extraordinary growth: from March 2025 to March 2026, the litigation grew from 78 to 3,099 cases — a 3,873% increase in just one year. As of early 2026, plaintiffs’ lawyers reported holding nearly 10,000 unfiled claims, meaning the docket is likely to continue expanding even as the settlement process gets underway.
Monthly case management conferences have been held throughout 2026 at the U.S. District Courthouse in Pensacola, Florida, per the court’s pretrial orders. On March 6, 2026, the Court held its eleventh Case Management Conference in the litigation — a joint CMC held alongside the courts of New York and Delaware. Five pilot bellwether cases were selected to represent the broader plaintiff pool, including Blonski v. Pfizer — in which a patient who began using the drug in 2002 was later found to have developed two meningiomas — and Wilson v. Pfizer, where a woman who used Depo-Provera from 1998 to 2019 suffered a stroke that revealed a Grade 1 meningioma. The first bellwether trial, Toney v. Pfizer, had been set for December 7, 2026, but its deadlines were vacated after the settlement agreement was announced in June.
A significant regulatory development occurred in December 2025, when the FDA added a meningioma warning to the Depo-Provera label — a change that has strengthened the position of plaintiffs whose claims were not yet filed and undermined one of Pfizer’s core defenses going forward. Women who suffered brain injuries linked to Depo-Provera use may want to use a brain injury calculator to get a preliminary sense of what their claim may be worth before consulting legal counsel.
The June 2026 Global Settlement: What It Does and Doesn’t Mean
In June 2026, Pfizer and attorneys representing thousands of women told a federal court they had reached a global settlement agreement in the Depo shot litigation — the most significant development in this case so far. On June 15, 2026, Judge M. Casey Rodgers announced in a court order that Pfizer and plaintiffs’ lead counsel have reached a global agreement to resolve eligible claims in the Depo-Provera MDL, though the terms have not yet been made public as both sides work to finalize the details. The Master Settlement Agreement was formally signed on July 21, 2026. In a further sign of the settlement process advancing, BrownGreer PLC was appointed as settlement administrator on August 5, 2026, and settlement registration is scheduled to open in November 2026.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.